TNFRSF10B antibody (Tumor Necrosis Factor Receptor Superfamily, Member 10b)

Details for Product anti-TNFRSF10B Antibody No. ABIN1383914, Supplier: Log in to see
Antigen
  • TNFRSF10B
  • dr5
  • cd262
  • killer
  • trick2
  • trickb
  • xDR-M1
  • xDR-M2
  • ztnfr9
  • trailr2
  • trick2a
  • trick2b
  • CD262
  • DR5
  • KILLER
  • KILLER/DR5
  • TRAIL-R2
  • TRAILR2
  • TRICK2
  • TRICK2A
  • TRICK2B
  • TRICKB
  • ZTNFR9
  • Ly98
  • MK
  • tumor necrosis factor receptor superfamily, member 10b
  • Tnfrsf10b
  • TNFRSF10B
  • tnfrsf10b-b
  • tnfrsf10b
Alternatives
anti-Human TNFRSF10B antibody for Flow Cytometry
Reactivity
Human
324
76
26
1
1
1
1
1
Host
Mouse
181
168
10
6
6
2
Clonality (Clone)
Monoclonal ()
Conjugate
This TNFRSF10B antibody is un-conjugated
23
20
16
6
5
5
5
4
4
4
4
4
4
4
4
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
Application
Flow Cytometry (FACS)
195
162
73
52
39
32
27
26
15
13
13
4
4
4
3
3
2
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Clone B-K29
Isotype IgG1
Specificity Recognises the 42-46 kDa protein
Characteristics Recombinant human TRAIL R2/Fc chimera.
Purification Ion exchange chromatography
Alternative Name CD262 (TNFRSF10B Antibody Abstract)
Background Myeloma X63/AG.8653 x Balb/c spleen cells
Molecular Weight 42-46 kDa
Pathways p53 Signaling, Apoptosis, Positive Regulation of Endopeptidase Activity
Restrictions For Research Use only
Format Liquid
Buffer Phosphate-buffered saline with 1 % BSA and 0.09 % sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Use 10 µL of (diluted) antibody to label 10 6 cells or 100 µL of whole blood
Storage 4 °C
Storage Comment Declared stable after 7 days at room temperature. Protect from light. Do not freeze.
Expiry Date 1 week
Product cited in: Ueda, Kohanbash, Sasaki, Fujita, Zhu, Kastenhuber, McDonald, Potter, Hamilton, Lotze, Khan, Sobol, Okada: "Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Issue 26, pp. 10746-51, 2009 (PubMed).

Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: "Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2." in: Molecular and cellular biology, Vol. 26, Issue 19, pp. 7046-55, 2006 (PubMed).

Did you look for something else?